A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause

Participant flow chart

^a The total is > 100%; some women were excluded for multiple reasons; ^b The mITT population included all randomly assigned participants who took at least 1 dose of the study drug and had ≥ 5 days of vasomotor symptom data at baseline and ≥ 5 on-therapy days of vasomotor symptom data during the first 12 weeks.

Archer. Desvenlafaxine efficacy and safety for vasomotor symptoms in menopause. Am J Obstet Gynecol 2009.

Decrease in number of moderate to severe hot flushes over 12 weeks, mITT population, last observation carried forward

^a The significant decrease for both desvenlafaxine 100- and 150-mg/d groups compared with placebo. Error bars indicate standard error. The 100- and 150-mg/d desvenlafaxine groups had significantly greater decreases than the placebo group at all time points (all comparisons, P ≤ .012). mITT, modified intent to treat.

Archer. Desvenlafaxine efficacy and safety for vasomotor symptoms in menopause. Am J Obstet Gynecol 2009.

Responder analysis, mITT population, last observation carried forward

A, Percentage of women with ≥ 50% decrease in average daily number of moderate to severe hot flushes. B, Percentage of women with ≥ 75% decrease in average daily number of moderate to severe hot flushes. The number of women who responded with a decrease of ≥ 50% and ≥ 75% in the average daily number of moderate and severe hot flushes was significantly greater in each desvenlafaxine treatment group than in the placebo group at weeks 4 and 12 (all comparisons, P < .001). ^a Significantly different from placebo. mITT, modified intent to treat.

Archer. Desvenlafaxine efficacy and safety for vasomotor symptoms in menopause. Am J Obstet Gynecol 2009.